ArticleInternational journal of molecular sciences2018
BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 27 citations in OpenAlex.
- Redifferentiation-enabled TSHRCART cells overcome antigen loss in aggressive thyroid cancers.Molecular cancer · 2026Article
- Jaceidin Suppresses Melanoma Metastasis by Modulating ERK, JNK Pathways and Extracellular Matrix Degradation Proteins.Journal of cellular and molecular medicine · 2026Article
- BRAF mutation and tumor immune microenvironment in new era.American journal of cancer research · 2026Review
- A Proteomics Outlook on the Molecular Effectors of CAR-T Cell Therapy in Cancer Management.Journal of proteome research · 2025Review
- Article
- MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB.Signal transduction and targeted therapy · 2024Article
- Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma.Cancers · 2024Review
- Advancements and Challenges in Personalized Therapy forJournal of clinical medicine · 2024Review
- Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.Molecular oncology · 2024Review
- Development of Personalized Strategies for Precisely Battling Malignant Melanoma.International journal of molecular sciences · 2024Review
- Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.Methods in molecular biology (Clifton, N.J.) · 2024Article
- GD2-targeting therapy: a comparative analysis of approaches and promising directions.Frontiers in immunology · 2024Review
- ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights.Frontiers in immunology · 2024Review
- CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy.International journal of molecular sciences · 2023Review
- Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells.Cancers · 2022Article
- Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.BMC cancer · 2021Article
- BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation.International journal of molecular sciences · 2021Article
- Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.Cancer science · 2021Article
- Review
- The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BRAF and MEK inhibitors (BRAFi/MEKi), the standard treatment for patients with BRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.